These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 25345538)

  • 1. A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair).
    Bahceciler NN; Babayigit Hocaoglu A; Galip N
    Expert Rev Vaccines; 2014 Dec; 13(12):1427-38. PubMed ID: 25345538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
    Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
    J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.
    Bergmann KC; Demoly P; Worm M; Fokkens WJ; Carrillo T; Tabar AI; Nguyen H; Montagut A; Zeldin RK
    J Allergy Clin Immunol; 2014 Jun; 133(6):1608-14.e6. PubMed ID: 24388010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
    JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
    Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
    Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
    Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the development of specific immunotherapies for house dust mite allergies.
    Moingeon P
    Expert Rev Vaccines; 2014 Dec; 13(12):1463-73. PubMed ID: 25187166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
    Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
    Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
    Richards JR; Stumpf JL
    Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and efficacy of house dust mite AIT.
    Mosbech H
    Allergy; 2011 Jul; 66 Suppl 95():55-6. PubMed ID: 21668857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
    Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
    J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis.
    Klimek L; Mosbech H; Zieglmayer P; Rehm D; Stage BS; Demoly P
    Expert Rev Clin Immunol; 2016; 12(4):369-77. PubMed ID: 26788764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of House Dust Mite Allergens in Sublingual Allergy Tablets Is Highly Dependent on the Formulation.
    Ohashi-Doi K; Kito H; Du W; Nakazawa H; Ipsen H; Gudmann P; Lund K
    Int Arch Allergy Immunol; 2017; 174(1):26-34. PubMed ID: 28950271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effective Allergenic Reactivity of House Dust Mite Sublingual Immunotherapy Tablets Is Determined by Tablet Formulation.
    Kito H; Du W; Nakazawa H; Lund K; Ohashi-Doi K
    Biol Pharm Bull; 2019; 42(6):1030-1033. PubMed ID: 31155578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
    Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
    J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
    Eifan AO; Calderon MA; Durham SR
    Expert Opin Biol Ther; 2013 Nov; 13(11):1543-56. PubMed ID: 24099116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tablet-based sublingual immunotherapy for respiratory allergy.
    Prieto L
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():30-35. PubMed ID: 29146015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan.
    Okamoto Y; Kato M; Ishii K; Sato Y; Hata T; Asaka Y
    Immunotherapy; 2023 Nov; 15(16):1401-1414. PubMed ID: 37727966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.